Publications by authors named "N Fabiano"
The United States Food and Drug Administration approved xanomeline-trospium combination for schizophrenia on September-26-2024. We conducted a PRISMA 2020-compliant systematic review with random-effects meta-analysis on the efficacy and safety of xanomeline-trospium in randomized controlled trials in patients with schizophrenia (MEDLINE, EMBASE, Cochrane, PsycINFO, October-01-2024). Co-primary outcomes were Positive And Negative Syndrome Scale (PANSS) total score (standardized mean difference=SMD), and all-cause discontinuation (risk ratio=RR).
View Article and Find Full Text PDFArticle Synopsis
- * Both male and female schizophrenia patients faced higher risks of all-cause mortality, suicide, and natural causes, but no significant differences were found between the sexes in these risks.
- * Young females (<40) showed a notably higher mortality risk compared to older females, while males faced a much greater risk of dying from neurological disorders than females, indicating a need for better healthcare interventions.